Michael Meuli

Michael Meuli

Auto-generated profile, based on publicly available information

Michael Meuli

Institute of Medical Microbiology

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2021 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
DSDaniel Schäfle
Daniel Schäfle
PSPetra Selchow
Petra Selchow
BBBarbara Borer
Barbara Borer
MMMichael Meuli
Michael Meuli
ARAnna Rominski
Anna Rominski
PSPeter Sander
Peter Sander
Mycobacterium abscessus exhibits arr (ADP-ribosyltransferase)-dependent rifampin resistance. In apparent contrast, rifabutin (RBT) has demonstrated promising activity in M. abscessus infection models, implying that RBT might not be inactivated by Arr.

2 January 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
GPGregory A. Phelps
Gregory A. Phelps
MCMartin N. Cheramie
Martin N. Cheramie
DFDinesh M. Fernando
Dinesh M. Fernando
PSPetra Selchow
Petra Selchow
CMChristopher J. Meyer
Christopher J. Meyer
RLRichard E. Lee
Richard E. Lee
Mycobacterium abscessus(Mab), a nontuberculous mycobacterial (NTM) species, is an emerging pathogen with high intrinsic drug resistance. Current standard-of-care therapy results in poor outcomes, demonstrating the urgent need to develop effective antimycobacterial regimens. Through synthetic modification of spectinomycin (SPC), we have identified a distinct structural subclass of N-ethylene linked aminomethyl SPCs (eAmSPCs) that are up to 64-fold more potent againstMabover the parent SPC. Mechanism of action and crystallography studies demonstrate that the eAmSPCs display a mode of ribosomal inhibition consistent with SPC. However, they exert their increased antimicrobial activity through enhanced accumulation, largely by circumventing efflux mechanisms. The N-ethylene linkage within this series plays a critical role in avoiding TetV-mediated efflux, as lead eAmSPC 2593 displays a mere fourfold susceptibility improvement againstMabΔtetV,in contrast to the 64-fold increase for SPC. Even a minor shortening of the linkage by a single carbon, akin to 1st generation AmSPC 1950, results in a substantial increase in MICs and a 16-fold rise in susceptibility againstMabΔtetV. These shifts suggest that longer linkages might modify the kinetics of drug expulsion by TetV, ultimately shifting the equilibrium towards heightened intracellular concentrations and enhanced antimicrobial efficacy. Furthermore, lead eAmSPCs were also shown to synergize with various classes of anti-Mabantibiotics and retain activity against clinical isolates and other mycobacterial strains. Encouraging pharmacokinetic profiles coupled with robust efficacy inMabmurine infection models suggest that eAmSPCs hold the potential to be developed into treatments forMaband other NTM infections.

9 January 2026 in ACS Infectious Diseases
Verified
Journal Article
Closed access
AKAnastassia Kraimps
Anastassia Kraimps
TGTizian Griesser
Tizian Griesser
RWRui Wang
Rui Wang
SDSilvia Dittmann
Silvia Dittmann
JCJordan Costafrolaz
Jordan Costafrolaz
KGKarl Gademann
Karl Gademann